David Hepworth

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin et al. · Nature Chemical Biology · 2015 · 850 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +12

Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation

Michael J. Primiano, Bruce A. Lefker, Michael Bowman et al. · The Journal of Immunology · 2016 · 178 citations

Life Sciences, Immunology, Pharmacology +17

Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay

J. Perry Hall, Amy Brault, Fabien Vincent et al. · PLoS ONE · 2017 · 162 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

The use of unretted hemp fibre in composite manufacture

David Hepworth, R.N. Hobson, D.M. Bruce et al. · Composites Part A Applied Science and Manufacturing · 2000 · 156 citations

Natural Sciences, Materials Engineering, Materials Science +10

Discovery of Clinical Candidate 1-{[(2 <i>S</i> ,3 <i>S</i> ,4 <i>S</i> )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Katherine L. Lee, Catherine M. Ambler, David R. Anderson et al. · Journal of Medicinal Chemistry · 2017 · 145 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17